Gene expression profiling has been used for the first time to stratify patients with systemic lupus erythematosus (SLE) into potentially useful clinical groups, and also to further understand differences in the cell-specificity and nature of the interferon signature typical of SLE and other autoimmune diseases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
de Jong, T. D. et al. Physiological evidence for diversification of IFNalpha- and IFNbeta-mediated response programs in different autoimmune diseases. Arthritis Res. Ther. 18, 49 (2016).
Flint, S. M. et al. Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases. RMD Open 2, e000183 (2016).
Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 1548–1550 (2016).
van Baarsen, L. G. et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3, e1927 (2008).
Wampler Muskardin, T. et al. Increased pretreatment serum IFN-beta/alpha ratio predicts non-response to tumour necrosis factor alpha inhibition in rheumatoid arthritis. Ann. Rheum. Dis. 75, 1757–1762 (2016).
Chaussabel, D. et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29, 150–164 (2008).
Coit, P. et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J. Autoimmun. 43, 78–84 (2013).
Acknowledgements
M.E.A.-R. is Head of the Management Entity of the Innovative Medicines Initiative Joint Undertaking project PRECISESADS under grant agreement n°115565, resources of which are composed of financial contributions from the European Union's 7th Framework Programme (FP7/2007-2013) and the European Federation of Pharmaceutical Industries and Associations in-kind contributions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.B. receives support from Sanofi/Genzyme in the context of a grant from the Innovative Medicines Initiative. M.E.A.-R. declares that she is in receipt of a grant from the Innovative Medicines Initiative that includes in-kind contributions by Bayer, Eli-Lilly, UCB Pharma, IRIS Servier and an in-cash contribution from Sanofi/Genzyme.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Barturen, G., Alarcón-Riquelme, M. Gene expression profiling comes closer to the clinic. Nat Rev Rheumatol 13, 69–70 (2017). https://doi.org/10.1038/nrrheum.2016.211
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.211
This article is cited by
-
New therapeutic strategies in systemic lupus erythematosus management
Nature Reviews Rheumatology (2019)